

Strong growth in medicinal cannabis sales continues

Bod is a cannabis centric healthcare company. With a global focus and a mission to innovate and transform the way we live and enjoy life. Delivering premium, proven and trusted products for both the consumer markets and medical markets. Leading the way in research and development, through collaborations with research partners on clinical trial programs.

Committed to supporting the healthcare professional on Cannabinoid applications with education, research and knowledge.

CAPITAL STRUCTURE

ASX code **BDA**
 Shares on issue 91.4m
 Market Capitalisation ~\$44.8m

BOARD & MANAGEMENT

Mr Mark Masterson
 Non-Executive Chairman

Ms Jo Patterson
 Chief Executive Officer

Mr Akash Bedi
 Non-Executive Director

Mr George Livery
 Non-Executive Director

Mr Patrice Malard
 Non-Executive Director

Mr Simon O'Loughlin
 Non-Executive Director

Mr Stephen Kelly
 Company Secretary

CONTACT

Level 1, 377 New South Head Rd
 Double Bay, NSW 2028

T +612 9199 5018

E info@bodaustralia.com.au

- **755 MediCabilis™ prescriptions filled during October – outlines a 106% increase in monthly prescription volumes since July 2019**
- **Total of 4,400 prescriptions filled since January 2020 – highlights a 124% increase on CY2019 volumes (CY2019 prescription volumes: 1,959)**
- **Repeat prescriptions accounted for 60% of October volumes outlining patient satisfaction**
- **Bod now has 57% market share in the market defined by full plant, high CBD products in Australia**

Sydney, Australia – 17 November 2020: Medicinal cannabis, CBD and hemp healthcare products company, Bod Australia Limited (“Bod”, or “the Company”) (ASX: BDA) is pleased to advise that it has continued its strong medicinal cannabis sales growth filling 755 MediCabilis™ prescriptions during October 2020. This outlines a 106% increase on the average monthly prescription volumes since July 2019 (average monthly volumes: 371)

October prescription volumes were part of the record purchase order received during Q1 FY2021 for 2,630 units (refer ASX announcement: 7 October 2020), which following delivery, will now be booked as sales.

Bod has now filled a total of 4,400 prescriptions since January 2020, which marks a 124% increase on CY2019 volumes (CY2019 total prescription volumes: 1,959). The ongoing upward trajectory in prescription volumes has significantly added to the Company’s revenue profile and demonstrates the traction that MediCabilis™ is gaining in the Australian market with a wide range of new and repeat patients.




Image one: cumulative units sold on a month-by-month basis

Repeat prescriptions for October accounted for 60% of the month’s total volume. This highlights patient and physician satisfaction with the product, as well as the benefits MediCabilis™ is delivering to patients by alleviating chronic conditions.

MediCabilis™ is being prescribed for a range of conditions and Bod now has a 57% market share in the addressable market defined by full plant, high CBD products in Australia. This is a major achievement given the highly competitive nature of the market.

Bod anticipates that strong MediCabilis™ sales growth will continue over the coming months in Australia due to the increased brand recognition being achieved, and the Company’s nationwide clinical observational study (refer ASX announcement: 16 July 2020).

CEO Jo Patterson said: “It is pleasing to see the continued growth and support for our medical cannabis product, MediCabilis™.

“While MediCabilis™ is being prescribed for a range of chronic conditions, we are currently achieving strongest uptake amongst patients suffering from chronic pain and anxiety. These conditions require the use of a pharmaceutical grade, standardised and consistent product, which is one of the key advantages of MediCabilis™.

“Strong demand for our MediCabilis™ product range in Australia will continue to add to our growing revenue profile and we are confident that sales will continue to increase. I look forward to updating shareholders on sales achievements across the coming months.”

- ENDS -

ABOUT BOD AUSTRALIA

Bod Australia Limited (ASX:BDA) Bod is a cannabis centric healthcare company.

With a global focus and a mission to innovate and transform the way we live and enjoy life.

Delivering premium, proven and trusted products for both the consumer markets and medical markets.

Leading the way in research and development, through collaborations with research partners on clinical trial programs.

Committed to supporting the healthcare professional on Cannabinoid applications through education, research and trials.

This announcement was authorised for release by the Board of Directors of Bod Australia Limited.

For more information please contact:

Jo Patterson
Chief Executive Officer
info@bodaustralia.com
+61 2 9199 5018

Henry Jordan
Six Degrees Investor Relations
henry.jordan@sdir.com.au
+61 431 271 538